158580-57-5

Usage

Uses

Used in Organic Synthesis:
METHYL 4-BROMO-2-NITROBENZOATE is used as a key intermediate in the synthesis of various organic compounds. Its functional groups facilitate multiple types of chemical reactions, making it a versatile component in the creation of a wide array of products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, METHYL 4-BROMO-2-NITROBENZOATE is employed as a building block for the development of new drugs. Its unique structure and reactivity contribute to the design and synthesis of potential therapeutic agents.
Used in Pesticide Production:
METHYL 4-BROMO-2-NITROBENZOATE is utilized as a chemical constituent in the formulation of pesticides. Its properties allow for the creation of effective agents against pests, contributing to agricultural productivity and crop protection.
Used in Dye Manufacturing:
METHYL 4-BROMO-2-NITROBENZOATE is also used in the production of dyes, where its chemical structure imparts color and stability to the final products. Its application in this industry is crucial for the development of new dyes with specific characteristics for various uses, including textiles and other materials.

InChI:InChI=1/C8H6BrNO4/c1-14-8(11)6-3-2-5(9)4-7(6)10(12)13/h2-4H,1H3

Upstream product

• 99277-71-1 4-bromo-2-nitrobenzoic acid 
• 77-78-1 dimethyl sulfate 
• 67-56-1 methanol 
• 74-88-4 methyl iodide 

Downstream Products

• 912575-10-1 2-nitro-4-vinyl-benzoic acid methyl ester 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 181871-73-8 methyl 4-methoxy-2-nitrobenzoate 
• 1312608-49-3 C₄₃H₅₃N₉O₆ 
• 1312610-92-6 C₄₅H₆₁N₇O₅Si 
• 1312608-64-2 C₄₂H₅₁N₉O₆ 
• 1312610-55-1 C₄₄H₅₉N₇O₅Si 
• 99847-13-9 3-nitrobiphenyl-4-carboxylic acid 
• 4445-43-6 3-amino-[1,1'-biphenyl]-4-carboxylic acid 
• 890314-33-7 3-(3,5-dichlorobenzamido)[1,1’-biphenyl]-4-carboxylic acid 
• 52449-76-0 2-nitro-4-cyanobenzoic acid methyl ester 
• 1402238-34-9 methyl 2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 

Relevant academic research and scientific papers

Tuning Lewis Acidity of Metal-Organic Frameworks via Perfluorination of Bridging Ligands: Spectroscopic, Theoretical, and Catalytic Studies

The Lewis acidity of metal-organic frameworks (MOFs) has attracted much research interest in recent years. We report here the development of two quantitative methods for determining the Lewis acidity of MOFs - based on electron paramagnetic resonance (EPR) spectroscopy of MOF-bound superoxide (O2?-) and fluorescence spectroscopy of MOF-bound N-methylacridone (NMA) - and a simple strategy that significantly enhances MOF Lewis acidity through ligand perfluorination. Two new perfluorinated MOFs, Zr6-fBDC and Zr6-fBPDC, where H2fBDC is 2,3,5,6-tetrafluoro-1,4-benzenedicarboxylic acid and H2fBPDC is 2,2′,3,3′,5,5′,6,6′-octafluoro-4,4′-biphenyldicarboxylic acid, were shown to be significantly more Lewis acidic than nonsubstituted UiO-66 and UiO-67 as well as the nitrated MOFs Zr6-BDC-NO2 and Zr6-BPDC-(NO2)2. Zr6-fBDC was shown to be a highly active single-site solid Lewis acid catalyst for Diels-Alder and arene C-H iodination reactions. Thus, this work establishes the important role of ligand perfluorination in enhancing MOF Lewis acidity and the potential of designing highly Lewis acidic MOFs for fine chemical synthesis.

Compound serving as protein kinase inhibitor and application of compound

The invention discloses a compound used as a protein kinase inhibitor and application of the compound, the compound has an obvious inhibition effect on protein kinase activity, can be used as a BTK inhibitor for preparing medicines for treating BTK-mediated diseases such as malignant tumors, autoimmune diseases and the like, and has wide application prospect.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

A pharmaceutical composition comprising the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is set forth. (Formula Ia), (Formula Ib), (Formula Ic), (Formula Id)

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

The Suzuki–Miyaura Cross-Coupling as the Key Step in the Synthesis of 2-Aminobiphenyls and 2,2'-Diaminobiphenyls: Application in the Synthesis of Schiff Base Complexes of Zn

2-Nitrophenylboronic acids serve as interesting starting materials for the construction of biphenyl- and terphenyl-based amines if subjected to the Suzuki–Miyaura reaction. Unfortunately, these boronic acids suffer from low reactivity in Suzuki reactions, alongside their low stability in the presence of Pd. Herein, a general method for the construction of 2-nitro-substituted bi- and terphenyls is presented, with special emphasis on the synthesis of 2-amino-2'-nitrobi- and terphenyls. Comparisons are made with other boronic acids that have some of the aforementioned issues. Finally, the application of the obtained 2-amino-2'-nitrobi- and terphenyls as starting materials for the synthesis of bi- and terphenyl based di- and triamines is encountered for, with emphasis on the use of these amines as precursors for Schiff base ligands. In addition, the synthesis of some Zn complexes of these ligands is presented.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

PROCESS FOR THE PREPARATION OF ORGANIC BROMIDES

The present invention provides a process for the preparation of organic bromides, by a radical bromodecarboxylation of carboxylic acids with a bromoisocyanurate.

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE

A compound of the general formula (I): [wherein, R1 represents a halogen atom, or the like, R2 represents a hydrogen atom, or the like, R3 and R4, each independently, represent a hydrogen atom, a C1-4